Opinion|Videos|May 2, 2025
FLAURA2 Maintenance: Key Strategies for Treatment Optimization and Patient Monitoring
Panelists discuss how FLAURA2 maintenance therapy strategies involve monitoring patients for toxicities and implementing dose modifications or schedule adjustments to improve tolerability.
Advertisement
Episodes in this series
Maintenance Therapy Strategies
Main Discussion Topics:
- Considerations when implementing the FLAURA2 regimen
- Management strategies for pemetrexed maintenance therapy
- Monitoring patients during maintenance treatment
Key Points for Physicians:
- FLAURA2 involves 4 cycles of carboplatin/pemetrexed followed by pemetrexed maintenance with osimertinib
- Key toxicities to monitor include leg edema, mucositis, and renal dysfunction
- Patient education and early intervention are crucial for managing toxicity
Notable Insights:
The flexibility to adjust maintenance therapy (dose reductions, treatment delays, or discontinuation) is an important aspect of optimizing the FLAURA2 regimen.
Clinical Significance:
Proactive monitoring and management of toxicities during maintenance therapy can help maintain treatment efficacy while preserving quality of life.
Advertisement
Related to this article
Researchers at Wake Forest University School of Medicine identified a protein that may help breast cancer spread to the brain and evade immune defenses.
Benjamin Weinberg, MD, discusses the FDA approval of daraxonrasib, RASolute 302 survival data, safety considerations, and future RAS-targeted therapies in pancreatic cancer.
Half of lenalidomide-refractory patients with 1 to 3 prior lines remained alive and progression free at least 5 years after a single cilta-cel infusion.
Andrew Kuykendall, MD, discusses the FDA approval of rusfertide and how to apply it in clinical practice for polycythemia vera management.
An NDA seeks FDA approval of savolitinib plus osimertinib for EGFR-mutated NSCLC with MET overexpression or amplification after EGFR TKI therapy.
Jason Hafron, MD, discusses the emotional, clinical, and financial burden of false positive cancer screening results and improved risk stratification.
Raajit K. Rampal, MD, PhD, discusses JAK inhibitor choice in cytopenic myelofibrosis, emerging combinations, and anemia-directed agents.
The sNDA for elinzanetant seeks FDA approval for moderate-to-severe vasomotor symptoms in women receiving endocrine therapy for HR-positive breast cancer.
Advertisement
Advertisement
Trending on OncLive
1
Ifinatamab Deruxtecan BLA Voluntarily Withdrawn in Previously Treated Extensive-Stage SCLC
2
China's NMPA Approves Pirtobrutinib Across CLL
3
FDA Grants Priority Review to Elinzanetant for Endocrine Therapy–Associated Vasomotor Symptoms in HR+ Breast Cancer
4
Long-Term PERSEUS Data Confirm Durable PFS Benefit With D-VRd in Transplant-Eligible Newly Diagnosed Myeloma
5